Lee Min Hee, Ahn Joong Mo, Chung Hye Won, Lim Hyo K, Suh Jae Gon, Kwag Hyon Joo, Hong Hyun Pyo, Kim Byung Moon
Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 108 Pyung-dong, Jongro-gu, Seoul 110-746, South Korea.
Eur J Radiol. 2007 Nov;64(2):309-14. doi: 10.1016/j.ejrad.2007.06.023. Epub 2007 Aug 6.
We evaluated follow-up magnetic resonance (MR) images for osteoid osteoma treated with percutaneous radiofrequency ablation (RFA).
Sixteen patients with osteoid osteoma treated with RFA underwent follow-up MR imaging. The protocol included T1, T2 and contrast-enhanced (CE) T1-weighted images with fat saturation at each visit immediately for 17 months after the treatment. MR images were jointly reviewed by two radiologists, regarding the appearance of treated areas, presence of complications, and the best sequence for visualization of signal intensity (SI) changes. The therapeutic response was evaluated to be a clinical success with the relief of pain.
The treated areas had a target-like appearance on MR images: a central ablated zone (Z1) surrounded by a band (Z2), and a peripheral area (Z3). Z1 was a non-enhancing, hypointense core on T1, T2WI. Z2 was a well-enhancing, hyperintense rim on T2WI. Z3 was less hyperintense and less enhanced than Z2. All nidi were within Z1. This appearance became evident from 1 week to 1 and 2 months. Following up after 2 months, Z2 showed progressive inward enhancement from the periphery, resulting in almost complete enhancement of Z1 and Z2 with a diminishing size. Z3 gradually showed a decrease in signal change and enhancement. No complications were found. CE-T1WI was the best for visualizing SI changes. The clinical success was achieved in all patients except for one patient with a recurrence at 17 months following treatment that had a second ablation.
MR imaging demonstrated a characteristic appearance and subsequent changes of treated areas for osteoid osteoma following RFA.
我们评估了经皮射频消融(RFA)治疗骨样骨瘤后的随访磁共振(MR)图像。
16例接受RFA治疗的骨样骨瘤患者接受了随访MR成像。该方案包括在治疗后立即进行每次随访时的T1、T2加权成像以及脂肪抑制对比增强(CE)T1加权成像,共持续17个月。两名放射科医生共同回顾MR图像,观察治疗区域的表现、并发症的存在情况以及用于观察信号强度(SI)变化的最佳序列。治疗反应被评估为临床成功,即疼痛缓解。
治疗区域在MR图像上呈现出靶样外观:中央消融区(Z1)被一条带(Z2)包围,以及一个周边区域(Z3)。Z1在T1、T2WI上是无强化的低信号核心。Z2在T2WI上是强化良好的高信号边缘。Z3的高信号和强化程度均低于Z2。所有瘤巢均位于Z1内。这种外观在1周后至1个月和2个月时变得明显。2个月后随访,Z2显示从周边向内部逐渐强化,导致Z1和Z2几乎完全强化且大小逐渐减小。Z3逐渐显示信号变化和强化程度降低。未发现并发症。CE-T1WI对于观察SI变化最为理想。除1例患者在治疗后17个月复发并接受了二次消融外,所有患者均取得了临床成功。
MR成像显示了RFA治疗后骨样骨瘤治疗区域的特征性表现及后续变化。